Ranirestat

Ranirestat

Ranirestat is an aldose reductase inhibitor that is used in the treatment of diabetic neuropathy. It is a synthetic drug that was developed by Sanwa Kagaku Kenkyusho Co., Ltd., a Japanese pharmaceutical company.

Mechanism of Action

Ranirestat works by inhibiting the enzyme aldose reductase. This enzyme is responsible for the conversion of glucose to sorbitol in the body. In individuals with diabetes, high levels of glucose can lead to an overproduction of sorbitol, which can cause damage to nerves and other tissues. By inhibiting aldose reductase, Ranirestat helps to prevent this damage.

Clinical Trials

Ranirestat has undergone several clinical trials to determine its efficacy and safety. In a Phase II trial, it was found to be effective in reducing symptoms of diabetic neuropathy and was well-tolerated by patients. A Phase III trial is currently underway.

Side Effects

As with any medication, Ranirestat can cause side effects. These may include nausea, dizziness, and headache. However, these side effects are generally mild and go away on their own. If they persist or become severe, patients are advised to contact their healthcare provider.

Contraindications

Ranirestat is contraindicated in individuals with a known hypersensitivity to the drug or any of its components. It should also be used with caution in individuals with renal impairment or hepatic impairment, as these conditions may affect the metabolism and excretion of the drug.

See Also

• Aldose reductase inhibitor
• Diabetic neuropathy
• Clinical trial

This article is a stub related to pharmacology. You can help WikiMD by expanding it!

   This article is a Diabetes-related stub. You can help WikiMD by expanding it!